BRNS (Barinthus Biotherapeutics plc American Depositary Shares) Stock Analysis - SEC Filings

Barinthus Biotherapeutics plc American Depositary Shares (BRNS) is a publicly traded Healthcare sector company. As of May 21, 2026, BRNS trades at $0.69 with a market cap of $26.08M and a P/E ratio of -0.42. BRNS moved +2.41% today. Year to date, BRNS is -5.52%; over the trailing twelve months it is -22.81%. Its 52-week range spans $0.51 to $2.92. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces BRNS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find BRNS SEC filings?

Rallies organizes BRNS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

BRNS Key Metrics

Key financial metrics for BRNS
MetricValue
Price$0.69
Market Cap$26.08M
P/E Ratio-0.42
EPS$-1.64
Dividend Yield0.00%
52-Week High$2.92
52-Week Low$0.51
Volume0
Avg Volume0
Revenue (TTM)$506.00K
Net Income$-66.46M
Gross Margin0.00%

Latest BRNS News

BRNS Analyst Consensus

1 analysts cover BRNS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.

Common questions about BRNS

Where can I find BRNS SEC filings?
Rallies organizes BRNS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show BRNS 10-K and 10-Q filings?
Rallies organizes BRNS SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is BRNS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BRNS. It does not provide personalized investment advice.
BRNS

BRNS